Institutional Implementation: Setting Up Tarlatamab Administration

EP: 1.ES-SCLC vs LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis

EP: 2.Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC

EP: 3.Addressing Critical Unmet Needs in ES-SCLC Patient Management

EP: 4.Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC

Now Viewing

EP: 5.Institutional Implementation: Setting Up Tarlatamab Administration

EP: 6.Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation

EP: 7.Patient Selection Criteria: Identifying Appropriate Candidates for Tarlatamab

EP: 8.Tarlatamab Administration and Postinfusion Monitoring

EP: 9.Essential Patient and Caregiver Education for Tarlatamab Treatment Success

EP: 10.Neurological Toxicity Recognition: ICANS Assessment and Management

EP: 11.CRS Recognition and Intervention: Timing and Clinical Features

EP: 12.Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue

EP: 13.Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies

EP: 14.Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS

EP: 15.Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management

EP: 16.Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum

EP: 17.Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit

Summary for Physicians:

Protocol for Tarlatamab Administration:

• Site Setup:
• Pretreatment screening: Ensure patients meet eligibility, assess organ function, and check for contraindications.

• Staff training: Ensure all staff are trained on administration protocols and handling potential toxicities.

• Monitoring: Patients are monitored for immune-related adverse effects such as cytokine release syndrome (CRS), especially during the first dose.

Challenges:

• Management of CRS:
• Need for rapid intervention and close monitoring in case of severe reactions.
• Patient Education:
• Ensuring patients understand potential adverse effects and the importance of timely reporting.
• Infrastructure:

Need for specialized facilities and equipment for infusion and monitoring, especially in the event of adverse reactions.